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Overview of
Workbook Series
This workbook is part of a series
intended to educate programme
planners, managers, staff and other
decision-makers about the evalua-
tion of services and systems for the
treatment of psychoactive substance
use disorders. The objective of this
series is to enhance their capacity
for carrying out evaluation activities.
The broader goal of the workbooks
is to enhance treatment efficiency
and cost-effectiveness using the in-
formation that comes from these
evaluation activities.
This workbook (Workbook 8) is
about economic evaluation. Eco-
nomic evaluations involve the iden-
tification, measurement and valu-
ation, and then comparison of the
costs (inputs) and benefits (out-
comes) of two or more alternative
treatments or activities.
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What is an
economic
evaluation?
Economic evaluations involve the identifica-
tion, measurement, and valuation, and then
comparison of the costs (inputs) and ben-
efits (outcomes) of two or more alternative
PSU treatments or activities.
In economic evaluations, the costs and con-
sequences of alternative interventions or sce-
narios are compared to examine the best use
of the scarce resources. The specific ques-
tion being addressed may be:
• a comparison of the costs and benefits of
a new intervention to some current thera-
peutic approach
• a comparison of the costs and benefits
between treatment and prevention activi-
ties
• a comparison of the costs and benefits
between treatment and law enforcement
activities
Economic evaluations differ according to
their scope and intent. They can have a
very narrow focus, whereby evaluators are
only concerned about the resource conse-
quences for their agency. In these evalua-
tions, any new intervention which shifts
costs to another agency may be preferred.
Alternatively, economic evaluations can
examine wider social costs. In these evalu-
ations, a new intervention that shifts costs
but does not reduce total costs may not
have good “value”. Similarly, for health
agencies, the outcomes of prime impor-
tance are likely to be the health of the indi-
vidual user. From a societal perspective,
however, the costs of crime and other so-
cial effects may be of greatest concern.
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Why do
an economic
evaluation?
Using any resource for the treatment of PSU
disorders means the opportunity to use that
resource for something else is lost. There-
fore, cost-effectiveness (or “value” for money
spent on treatment services) is of central con-
cern in most health care and government sys-
tems. Economic evaluation is one of the tools
available to help choose wisely from a range
of alternatives and implement efficient re-
sources.
In general, economists prefer the widest
possible societal perspective: general ques-
tions about the use of scarce resources and
societal well-being. However, in certain
cases, policy makers may wish to know
the answers to narrower questions, for
example, restricting the perspective to
health outcomes and health care expendi-
ture, or restricting it to a specific area, for
example, the effects on crime and the crimi-
nal justice system.
Economic
evaluation is
one of the
tools available
to help choose
wisely from a
range of
alternatives
and implement
efficient
resources.
Full economic evaluations are rarely com-
pleted. One reason is that economic evalua-
tions are resource intensive and typically re-
quire a high level of research expertise. It is
important, prior to undertaking this type of
study, to determine whether a full economic
evaluation is warranted or required. For some
research questions, answers can be ad-
dressed through a cost evaluation (Work-
book 5), which is generally less intensive to
complete.
Full economic evaluations should only be
undertaken after an initial analysis to gauge
the usefulness of the study. Prospective eco-
nomic analyses are best undertaken along-
side other evaluations, particularly outcome
studies (Workbook 7). In themselves, eco-
nomic components of research need not be
excessively expensive. There is, however,
great merit in examining the economic de-
sign from the beginning of a research plan-
ning process as results may affect the overall
design of the study as well as the detail of
data collection.
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How to do a
cost evaluation:
general steps
Before doing an economic evaluation, it
is important to review Workbook 1 of this
series, which outlines general steps to
evaluation planning. The specific steps
for undertaking economic evaluations
are outlined in this section.
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The main steps are:
1. Defining the economic question and the
perspective of the study
2. Determining the treatments to be evaluated
3. Choosing the study design
4. Identifying, measuring and valuing the costs of
the alternative treatments
5. Identifying, measuring and valuing the benefits
of the alternative treatments
6. Adjusting costs and benefits for differential
timing
7. Measuring the incremental costs and benefits
8. Putting the costs and benefits together and
analysing the results
9. Testing the sensitivity of the results
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1. Defining the economic question and
the perspective of the study
Your choice of study questions will depend
on the specifics of your situation and your
evaluation priorities. Use Workbook 1 to
help you define your specific evaluation goals.
Some pros and cons of different approaches
are discussed below.
You may want to know the cost of your own
programme, in your own organisational con-
text. While this approach is likely to gener-
ate some useful data, results generated from
such a study cannot be generalised across
services.
Alternatively, you may want to know whether
a new therapy should be adopted. The pro-
viders of substance use service may be in-
terested in the detailed analysis of the costs
and consequences for their own organisation.
Funders of services may be interested in the
wider implications for health service delivery
under their jurisdiction. National or state au-
thorities may be more interested in the soci-
etal perspective. It is important that you as-
sess the potential consequences of taking any
narrower perspective than that of society.
Questions about adopting a new treatment
can, depending on your situation, be put in a
number of different ways. For example, you
may have a set budget for substance use treat-
ments. In this situation, your question may
be whether a new treatment can deliver more
benefits within the same budget constraint as
other existing approaches. In other situations,
you may be more concerned with meeting a
health target and then the question may be
posed as to which type of therapy involves
the least net cost for some target level of
benefit.
More general questions, for example, about
the overall level of funding of substance use
treatments in a local area, or whether the
balance between prevention and treatment
funding is bringing the highest health gains,
require a broader approach and perspective.
Answering such broad questions requires
data at a more aggregate level and assumes
that many of the detailed evaluations have
already been undertaken.
2. Determining the treatments to be
evaluated
Full economic evaluations require two or
more PSU treatments for evaluation. The
choice of treatments is a very important part
of the evaluation process. An economic
evaluation is not useful if a potential treat-
ment of greater benefits and lesser costs has
been omitted. On the other hand, it is im-
possible, for practical reasons, to evaluate
all possible alternative PSU treatments.
A clear evaluation question for all new treat-
ments is: what are the costs and outcomes of
the new treatment compared to current prac-
tice? (Sometimes this is interpreted as cur-
rent “best” practice.) For more fundamental
questions of the value of treatment, the ques-
tion may imply a comparison with a no-treat-
ment option. This implies, however, a full
evaluation of the no-treatment alternative. For
example, a certain proportion of the group
may stop taking PS or reduce the harm as-
sociated with their PSU without formal treat-
ment. However, obtaining data on a sample
receiving no-treatment is difficult, and re-
search including such a no-treatment option
may be deemed unethical. In practice, there
Given the
current scarcity
of economic
evaluations,
it is important
to generate a
body of well-
conducted
research.
However, such
studies need to
be resourced at
an appropriate
level.
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is usually some attempt to evaluate the new
therapy compared to some form of minimal
intervention.
The case example located at the end of this
workbook presents an evaluation of a rela-
tively new case approach versus “usual care”
for people with severe mental illness and PS
dependence. “Usual care” was defined as
participation in a community-based PSU sup-
port group (alcoholics/narcotics anonymous).
Some questions require more complex
evaluation designs. For example, you may
want to evaluate a system of treatments or
some form of stepped care. These types of
questions lend themselves to a decision-tree
approach. Zarkin and colleagues (1994) cre-
ated one structure to consider the impact of
evaluating outcomes and costs over more
than one treatment episode. This approach
assumes that a PSU client will have repeated
encounters with treatment services through-
out his/her lifetime, and helps to identify al-
ternative PSU policy interventions that might
affect outcomes. Considering any one PSU
client’s lifetime history, he/she will be on a
particular “branch” of a decision tree at any
given time (e.g., A) stopped PSU after initial
treatment vs. B) continued to use PS after
initial treatment and was admitted for further
treatment vs. C) continued to use PS after
initial treatment but refused additional treat-
ment. By estimating the proportion of the total
client population that may follow each of
these paths, you can examine the effect of
potential policy changes in terms of numbers
of clients affected, costs, and expected out-
comes. For example, you can assess the pro-
portion of your PSU population that is clas-
sified into category C (above), and estimate
whether an intervention directed at motivat-
ing this category of patients to return to treat-
ment is as cost effective as directing similar
resources at initial intervention efforts.
Alternative structures could be composed
looking, for example, at the potential differ-
ent outcomes from compliance to mainte-
nance therapies. Glazer and Ereshefsky
(1996) present a model with antipsychotic
therapy that could be adapted. In their model,
the first step is to identify all the treatments in
current clinical practice, then to identify the
possible outcomes of each of the treatment
alternatives (e.g., client will comply or not
comply, client will remain abstinent from PSU
or begin using PSU again, etc.). The next step
is to establish the estimated probability of
each of the outcome combinations (or “path-
ways”) for each treatment alternative. Ide-
ally, these probabilities should be derived
from previous outcome evaluations (Work-
book 7). Costs for each treatment alterna-
tive are compiled separately. Finally, costs
for each treatment alternative are compared
by multiplying the costs associated with each
outcome pathway by the cumulative prob-
ability that a client will reach this particular
outcome. After repeating this process for
each of the outcome pathways associated
with each treatment alternative, costs can be
added together to yield the total cost of that
treatment strategy.
Another approach would be to use a deci-
sion analysis to evaluate a stepped care
programme where “failures” are entered into
different or progressively more intensive
therapies. The advantage of the decision- tree
approach is that thought must be given to all
the alternative courses. The disadvantage is
that data are required on the probabilities of
outcomes at different stages and for evalua-
tion to be feasible at each of these stages.
Given the current scarcity of economic evalu-
ations, it is important to generate a body of
well-conducted research. However, studies
such as these need to be resourced at an
appropriate level. The danger is that with so
few studies conducted, the results of a study
that is designed to answer a very specific
question, with very selected alternatives be-
ing considered, may be inappropriately
generalised.
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3. Choosing the study design
Many existing studies fall short of full eco-
nomic evaluations. Drummond and col-
leagues (1997) outlined different types of
partial evaluations and emphasised two char-
acteristics necessary for full economic evalu-
ation:
• a comparison of two or more alternatives
• both costs and benefits of the alternatives
are considered
No intervention can be cost-effective if it is
not effective in terms of clinical outcomes (see
Workbook 7). Therefore, the most robust
design for a full economic evaluation is a
randomised controlled trial. This is the de-
sign that was used in the case example evalu-
ation located at the end of this workbook.
Other evidence of cost-effectiveness is less
robust. In particular, studies using differences
between before and after treatment, with no
control group, tend to overestimate benefits
of treatment. These benefits are even more
prone to overestimation if only those who
complete treatment are included in the study.
Ideally, cost data is collected at the same time
and with the same degree of accuracy as
outcome data. While this is increasingly be-
coming the practice, most studies have ei-
ther attempted to estimate costs for alterna-
tive therapies retrospectively, or model costs
and consequences for the alternatives being
considered using literature reviews of effec-
tiveness data and models of resource costs.
For more complex structures, or where there
are longer term benefits, some modelling and
model predictions will always be required.
Any modelling or predictions require some
assumptions to be made.
Part of the study design stage involves the
choice of an economic evaluation method:
cost-minimisation; cost-effectiveness; cost-
utility or cost-benefit (described below).
There is a need to match the choice of eco-
nomic analysis to the questions being ad-
dressed in the analysis. For example, if the
question is about the best way to improve
the health of PSU users, a cost-effectiveness
design may be adopted. However, if there
was a need to make wider comparisons it
may be more appropriate to use a cost-util-
ity framework. For studies attempting to look
at the full range of costs and benefits of pro-
viding treatment compared to no treatment,
the most appropriate design may be cost-
benefit analysis.
There are four types of full economic evalu-
ation:
• cost minimisation
• cost-effectiveness
• cost-utility
• cost-benefit
The main difference between the four types of
full economic evaluation is how the benefits to
the individual are measured and valued.
Cost minimisation analysis
In cost minimisation, the effect of the alter-
native interventions on the individuals health-
related quantity and quality of life are as-
sumed to be equal. In these studies, all other
resource consequences are measured in
monetary terms. Some of these resource
consequences, such as reduced future levels
of crime or health care costs, can be seen as
“benefits” of the intervention, whereas other
aspects such as the direct costs of the inter-
ventions can be clearly defined as “costs.”
Published studies vary in the name given to
some of the non-individual “benefits” — in
some studies these are considered as part of
the cost calculations but as benefits these sums
are subtracted from other costs to give a net
costs total.
Only where
there are two
or more
alternatives,
and both costs
and benefits
are examined,
is the study
classified as a
full economic
evaluation. It is
only from full
economic
evaluations
that questions
about value for
money can be
addressed.
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If two interventions have the same individual
health effects, then the one which can be judged
as the most value for money will be the inter-
vention which minimises the net costs. It is, how-
ever, a strong assumption to assume that indi-
vidual health effects are the same between two
or more alternative treatments (or treatment
scenarios if more complex questions are being
posed). It would be an even stronger assump-
tion to include all other benefits of treatment as
equal. The advantage of the cost minimisation
approach is that the measurement problem is
reduced to just examining resource conse-
quences. However, the assumptions are diffi-
cult to justify prior to any experimental study.
This method, therefore, has only limited appli-
cation within the PSU field.
An example of a cost minimisation study is
an examination of several standard metha-
done facilities in which client group and
expected consequences are assumed to be
the same. The figures in the table on the
next page illustrate some potential results.
They are taken from a study by Bradley
and colleagues (1994), and it should be
stressed that this study was only concerned
with costs and no claims were made about
the outcomes of the different sites. Of the
three sites reported in the table below, Site
A was hospital based whereas Sites B and
C were free standing facilities. In this case,
Site A is the cost minimising option, be-
cause of the lower average staff costs.
Cost-effectiveness Analysis
The majority of the published economic
evaluations have been cost-effectiveness
analyses. In this type of economic evalua-
tion, the effect of treatment is measured in
a single natural health unit. Costs and other
consequences also are measured in mon-
etary terms in the same way as for cost
minimisation analysis. The requirement for
an economic study to have a single, prin-
cipal outcome measure is needed to con-
The advantage
of the cost
minimisation
approach is
that the
measurement
problem is
reduced to just
examining
resource
consequences.
However, the
assumptions
are difficult to
justify prior to
any
experimental
study.
Site A Site B Site C
Capital cost
Rent and maintenance
Staff costs
Telephone, office supplies, utility costs etc.
Contracted services
(laboratory tests, pharmacists, accountants etc)
TOTAL Costs
Number of clients
Average cost per client
Illustrative cost minimisation analysis for 3 standard methadone
treatment programmes (1990)
17,190
44,876
663,257
111,298
131,645
968,266
250
3,873
83,107
102,326
843,323
199,206
237,205
1465,167
333
4,400
105,340
6,508
414,812
222,273
39,339
788,272
210
3,754
struct some cost-effectiveness ratio indi-
cating the net costs required for each unit
of outcome. For some health care inter-
ventions, the natural health unit outcome
measure may be best reflected by deaths
avoided or gains in life years. Most PSU
studies have used some measure of PSU
rather than a health measure, for example,
the net costs per abstinent day, or per per-
centage reduction in PSU.
15Workbook 8  •  Economic Evaluations
WHO/MSD/MSB 00.2i
One down side of this technique is that using
a single measure is that the total effects of
PSU treatment may not be reflected in any
one health or PSU variable. Further, many
of the effects of treatment on the individual
may have wider impact on the quality of life
than just that of health. Hence, a narrow uni-
dimensional outcome measure used as a
comparison may fail to “measure” the full
impact of the different therapies and lead to
a misleading conclusion on the relative
“worth” of the therapies under consideration.
The choice of outcome measure not only af-
fects the validity of the study, but also the
use of study results. PSU quantity measures
may be preferred by therapists as being the
only measures relevant to their client group.
However, funders of treatment could not use
such studies to examine the comparative
worth of expanding PSU treatments vs. ex-
panding vaccination programmes because of
the lack of a common generic health status
measure.
To illustrate the use of cost-effectiveness
studies, consider the following example of the
effectiveness of brief interventions compared
to a control intervention for those drinking
alcohol above a low risk level. In this ex-
ample, both costs and effects are measured
as the excess over the control intervention.
• Systematic reviews of the effectiveness
evidence suggest that alcohol consump-
tion is reduced on average by 20 per cent
following brief interventions. Assume that
in a hypothetical problem- PSU popula-
tion, this would translate into a reduction
of 6.02 alcohol units per person per
week. (One unit is equal to 8 grams of
alcohol).
• Based on these results, administrators
want to implement a screening
programme and delivery opportunistic
brief interventions in a primary care set-
ting for 100 men and 100 women. Be-
fore doing so, they want to understand
the cost-effectiveness.
In this type
of economic
evaluation,
the effect of
treatment is
measured in a
single natural
health unit.
Costs and
other
consequences
also are
measured in
monetary terms
in the same
way as for cost
minimisation
analysis.
• The screening costs of applying an alco-
hol use questionnaire, 2 minutes, are cal-
culated to be between £0.8 and £2.40
per person, total costs £160 to £480.
• The questionnaire is estimated to suggest
that 46 people would need a brief inter-
vention (36 true positive and 10 false
negative)
• It is estimated that 15 minutes is needed
to deliver each intervention, with addi-
tional costs of leaflets, etc., giving a cost
of each brief intervention of between £8
and £20
• For the 46 people receiving the interven-
tion, this yields a service cost of between
£368 and £920
• Total programme costs including the
screening are therefore between £528 and
£1400
• The cost per at risk drinker is between
£14.6 and £38.9
• Expressing this in terms of effectiveness
evidence yields an average extra costs of
£2.4 to £6.5 per “unit” of reduced alco-
hol consumption.
Note this example is conducted from the pri-
mary care perspective and only a limited
range of cost and consequences are exam-
ined.
Cost-utility Analysis
All resources have an opportunity cost: op-
portunities to do something different with re-
sources are lost when resources are com-
mitted in a certain direction. Within health
care, there is a need to make decisions on
the balance of resources, for example, be-
tween terminal care and prevention interven-
tions. Such comparisons, however, require
some common outcome measures that can
incorporate quantity and quality of life
changes. Such measures can be seen as mea-
sures of utility (or value of health) to indi-
viduals. Economic evaluations using such
outcome measures are hence called cost-
utility studies.
16 Evaluation of Psychoactive Substance Use Disorder Treatment
WHO/MSD/MSB 00.2i
Drummond et al (1997) suggest this method
should be used when quality of life is the
important outcome. PSU cost-utility studies
might involve the evaluation of social care
programmes designed to help individuals
who have been in long-term residential
programmes. Or, it might be used to com-
pare interventions that have effects both on
the length and quality of life. Finally, there
are those programmes that have a range of
different outcomes arising from interventions
and some common measure is required to
make comparisons between them.
There are a number of different aspects to
constructing and using health utility measures
in economic evaluations. It is necessary to
identify, measure, and value the health gains
from any extension of life and improved qual-
ity of life. Some treatments may improve both
aspects, but others may influence only the
length of life or the quality of life. Whereas
cost-effectiveness studies measure the out-
come a particular point in time, for example
one year after treatment ends, cost-utility
measures must estimate how long the treat-
ment effects will last.
Most cost utility studies measure quality
adjusted life years (QALYs) among their
participants. A QALY is based on the idea
that categorising people merely as “alive” or
”dead” (i.e., quantity of life) does not cap-
ture adequately multiple states of health, or
quality of life, that exist in individuals’ lives
following PSU treatment. QALYs assign the
score of 1.000 to a (hypothetical) person
who is in a state of perfect health. Then, de-
ductions from 1.000 are taken for different
symptom reports while answering quality of life
questions. For example, use of a cane may re-
duce a person’s QALY by.060 (1.000 -
0.060), while wheezing or shortness or breath
may reduce QALY by.257 (1.000 - 0.257).
Note that not all QALYs are calculated in
the same way. Scoring for different ques-
tionnaires may be based on different ideas
about what constitutes quality of life. For
example, is regular fainting “worse” than
chronic pain? Different quality of life mea-
sures will “weight” or value these items dif-
ferently. Different QALY measures also
have different health dimensions. The
EuroQol EQ-5D, for example, has 5 di-
mensions: mobility, self-care, usual activ-
ity, pain/discomfort and anxiety/depression
(Dolan et al., 1995). Another measure, the
WHOQOL-BREF, has four dimensions:
physical health, psychological, social rela-
tionships, and environment. Copies of both
measures and scoring instructions are lo-
cated in Workbook 1, Appendix 2.
All other costs and resource consequences
are measured and valued in a similar way
as in all the other types of economic evalu-
ations.
As an example of this type of study, con-
sider the three treatment programmes de-
scribed in the previous cost-minimisation
table. If a cost utility study of these three
programmes were completed, it would have
been possible to chart both differences in any
overdose or other mortality while in the
programme and the improvement in general
health.
Using this example, assume that Site C (with
greater proportionate staff input) resulted in
each client having large health improvements
using a standard quality of life measures.
Combining the health and reductions in mor-
tality yielded the following average total health
gains in the three programmes over a year
programme. No future health gains were
thought to arise from these programmes, a
minimum estimate position.
.. this method
should be
used when
quality of life
is the
important
outcome.
Site A 160 QALYs (210 original clients)
Site B 291 QALYs (333 original clients)
Site C 345 QALYs (250 original clients)
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Combining these findings with cost data
(assuring the original cost figures were ad-
justed for the premature mortality (and
hence reduced annual cost) yielded the
following average cost per QALY figures
shown in the table below.
All other costs and consequences are as-
sumed to be the same between the sites. In
this example, Site C has a far lower cost per
QALY than the other two sites. Given the
different mortality rates, there would be dif-
ferential health gains in future years even if all
existing clients reverted back to former lev-
els of PSU.
Cost-benefit Analysis
In cost-benefit analysis, all individual benefits
are measured in monetary terms. This means
that all costs and consequences are measured
in the same units. The method is useful when
there are a wide range of diverse outcomes
associated with the treatments being evalu-
ated. Because the results can be expressed
in terms of whether the monetary value of
benefits outweighs the costs, such studies are
often seen to provide more powerful argu-
ments for implementing programmes (or not)
than other forms of economic evaluation.
However, the relevance of any study to de-
cision-making depends on the alternative
options being evaluated and the scope of the
evaluation.
Measuring health gains in monetary terms is
sometimes viewed as problematic. For ex-
ample, market values of the value of life,
based on foregone earnings have been
thought to undervalue some groups in soci-
ety, particularly older and poorer people.
This method of valuation is now rarely used.
Other methods include using market values
Illustrative example of a cost utility study
Total Programme QALYs gained Average cost
costs ($) per QALY ($)
Site A 788,272 160 4,927
Site B 1,465,167 291 5,035
Site C 968,266 345 2,807
of risk or asking individuals to put monetary
values on different health states using a will-
ingness-to-pay approach (see Johannesson
et al. (1996) for a review of these methods).
An illustration of the results gained by will-
ingness to pay methods can be drawn losses
associated with fatal road accidents in the
United Kingdom. The government agency
reviewed the available estimates from all dif-
ferent methods, and choose a value in 1987
of £500,000 per life. This compared to a fig-
ure of £283,000 calculated using a foregone
earnings method. In 1996 terms, this con-
verts to a value of £23,000 for each lost
(gained) life year.
Willingness-to-pay methods may be seen as
an alternative measurement system to that
used for utility measures. The differences
between them may be in the weighting sys-
tem used for different groups of the popula-
tion. Utility measures usually have an equity
element built in, with one quality adjusted life
year being deemed of equal value to all indi-
viduals. This is not always the case with mon-
etary measures as some may be biased to
giving greater weight to those with more in-
come. This method may be appropriate in
health care systems were individuals are re-
sponsible for paying for health care.
French and colleagues (1996) have proposed
recently a method for estimating the mon-
etary value of PSU treatments. The method-
ology they proposed is a mixture between
In cost-benefit
analysis, all
individual
benefits are
measured in
monetary
terms.
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using health utility measures and monetary
valuations. Estimates of quality adjusted life
years are calculated for different age/gen-
der and race cohorts and a dollar value of
a QALY applied. The average value was
taken from assuming a value $5 million for
the statistical life of an average white male
at age 38. In essence, the methodology
proposed could be used within either a
cost-utility or cost-benefit analysis. Differ-
ent disease outcomes were related to a
general index of values of different health
states. For example, compared to a per-
fect health value of 1 and death as 0, a
moderately severe case of Hepatitis B was
thought to generate a value of 0.96 over 2
months duration. This is an interesting “low
cost” methodology for estimating individual
health gains. It may have useful applica-
tions for PS injection users who are vul-
nerable to a number of different diseases
with measurable consequences. It may be
possible to provide reasonable estimates
of the “avoided cases” by treatment. How-
ever, these data would need to be esti-
mated from available epidemiological data
and it is not clear that “avoided disease” can
be accurately estimated for the range of dif-
ferent PSU. Also, by concentrating on
avoided disease, the measure may fail to cap-
ture the full individual benefit of treatment.
This may be particularly important for treat-
ments applied to less dependent users.
The fullest study examining both costs and
benefits in monetary terms was conducted
by Gerstein and colleagues (1994). This
was a before and after study without a
control group and therefore can be
criticised on methodological grounds. The
study, however, illustrates the size of po-
tential gains to a number of agencies. Con-
sequences included criminal justice costs,
an estimate of victim losses from crime,
health care cost and productivity conse-
quences. The summary figures are given in
below, showing all modalities apart from
methadone discharge resulted in greater
benefits than costs for an average episode
of treatment.
CALDATA examples of cost benefit analysis
Residential Social Model Outpatient Methadone Methadone
Discharge Continuing
Savings per Day During $22.19 $12.79 $10.60 $14.14 $29.68
Savings per Day After $24.51 $14.43 $7.50 $-3.79 N/A
LOS (average) 69 79 150 60
Cost per Day of Treatment $61.47 $34.41 $7.87 $6.79 $6.37
Total Cost Per Episode $4,405 $2,712 $990 $405 $(2,325)
Total Benefits $10,744 $6,509 $2,853 $-1,206 $(10,833)
Benefits to Cost 2.44 2.40 2.88 -2.98 4.66
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Cost-offset, cost-outcome
and other types of partial
economic evaluations
There also are a number of valuable partial,
economic evaluations that have been under-
taken for PSU treatments. These are given
different names in the literature including cost-
offset and benefit-cost studies (often referred
to somewhat erroneously as cost-benefit
studies).
• An outcome description, a cost de-
scription or a cost-outcome description
is a study that examines only one treat-
ment (or possibly one treatment system).
• A cost analysis is a study that considers
one or more alternatives, and only costs
are examined (see Workbook 5).
• Cost-offset studies examine the costs of
different treatments or treatment systems
and the consequent impact on future health
care costs. The idea being tested is that
the costs of substance use treatments can
be fully or partly offset by reductions in
future health care costs. The purpose of
these studies is to lend support for the in-
clusion of coverage of alcohol and other
substance use treatments in insurance
plans. It is an attempt to partially address
the question is treatment worthwhile. In
general, the analysis has involved obser-
vational data on individuals through time
and comparing health care costs before
and after treatment.
Undertaking a partial economic cost study is
one practical way to collect data with limited
resources. Such data can give a broad pic-
ture of a service, although great caution is
needed in making any comparisons either
within the service or across services. Such
studies provide some evidence on the broad
worth of treatments while not being of suffi-
cient rigour to answer more detailed ques-
tions on how services could be changed to
yield more benefits with less resource use.
4. Identifying, measuring and valuing
the costs of the alternative treatments
Undertaking
a partial
economic
cost study is
one practical
way to
collect data
with limited
resources.
The table on the next page outlines all the
potential costs of a PSU treatment. The four
general areas identified where costs may
occur are:
• costs to service providers
• costs to the individuals and families in
treatment
• costs to other agencies or individuals
• productivity costs
20 Evaluation of Psychoactive Substance Use Disorder Treatment
WHO/MSD/MSB 00.2i
Checklist of costs of substance use treatments
1. Costs to service providers
• Capital
- land
- buildings
- equipment
• Running costs
- paid staff
- volunteers
- administrative and managerial costs
- consumables including drugs prescribed and their dispensing costs, toxicology
costs etc.
2. Costs to the individuals and their families in treatment
• Out of pocket expenses
- travelling and other direct expenses
- contribution to treatment costs (if not included in A)
• Leisure time and other costs associated with input to treatment Costs
- pain, distress etc. associated with changing habits, or with process of treatment
3. Costs to other agencies or individuals
• Referrals to other health or social agencies linked to the treatment
• Increases in potential problems associated with treatment
- leakage of prescribed drugs to illicit markets
4. Productivity costs
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The areas that may be included in your analysis
will depend on your situation. For example,
an evaluation from the health service per-
spective may only concentrate on the cost to
providers and any other consequent cost for
other health agencies. If a wider perspective
is taken, more variables may be analyses. In
these situations, it is important to avoid double
counting. For example, individuals may lose
income while undertaking treatment. Includ-
ing an allowance for the full cost of lost pro-
ductivity from the time spent in treatment
would mean that the lost labour “resource“
would be erroneously counted twice. It should
also be noted that the list refers only to “re-
source“ costs – those actions which mean
there is a loss of scarce raw materials, land,
labour or capital. Many PS users may be in
receipt of welfare payments from the state
— these are transfers from one group (the
taxpayer) to another group. Changes in
transfer payments are not included in eco-
nomic evaluations. However, such changes
may be of prime interest to state or na-
tional governments and may need some
separate analysis.
It may be relatively easy to measure and value
the provision of the costs of treatment. Some
other potential consequences pose more
problems. For example, it is often difficult to
trace the full impact of different treatments
on other agencies. Alternatively, certain treat-
ments may be associated with more distress
both to the individual and their family. While
it may not always be possible to measure and
value all these effects, some analysis can be
undertaken to check whether they are likely
to differ among the alternatives being evalu-
ated.
A controversial area is whether costs arising
from lost productivity while in treatment
should be included in different economic
evaluations. For long residential treatments,
the estimates of these costs can be consid-
erable. A sizeable group of substance users
in treatment may have been unemployed for
some time and therefore the valuation of this
item will depend crucially on whether the
estimates are based on some unadjusted
value of time, or adjusted for labour market
demand conditions – i.e. adjusted for the risk
of unemployment.
A number of questions also arise in applying
“values“ to material resources. For example,
some resources may be more expensive in
rural areas because of transportation costs
whereas others, including buildings, may be
more expensive in urban areas because of
scarcity. It is helpful to present results in re-
source use terms as well as applying mon-
etary values so that individual readers can
relate the results to their own situation.
More detail on how individual treatments
may be costed and further discussion of
some costing issues are contained in Work-
book 5.
It may be
relatively easy
to measure
and value the
provision of
the costs of
treatment.
Some other
potential
consequences
pose more
problems.
5. Identifying, measuring and valuing the
benefits of the alternative treatments
In the table on the next page, the range of pos-
sible benefits that may arise from treatment
is outlined. The five broad areas are:
• direct health benefits to the individual
• non-health improvements in quality of life
for the individual and family
• reduced use of other health care interven-
tions
• benefits to other agencies
• productivity benefits
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Consequences of PSU Treatments
1. Direct health benefits to the individual
• Quality and quantity of health improvements
- exact measurement depending on economic analysis type
- associated with reduction in drug use
- reduced risk of injection-transmitted disease
- more healthy lifestyle in general
- less any adverse effects of treatment
2. Non-health improvements in quality of life for the individual
and family
• Reduction in PSU- related violence
• Improvements in social functioning
• Other benefits to the family
3. Reduced use of other health care interventions
4. Benefits to other agencies
• Reduced use of resources from other social care and welfare services
• Reduced criminal justice system costs
• Benefits net of any adverse consequences to “community and social
environment”
5. Productivity benefits
• Benefits in individual productivity as a result of the treatment
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Most studies are likely to include a number
of different individual outcome measures. For
example, many controlled trials may include
some measure of substance use, some spe-
cific substance-related outcome measure and
a more generic health status instrument. For
economic evaluations, there may be a need
to value the health benefits and a need to
choose both the method of valuation and the
groups from which values are sought, for
example, from PS users or the whole popu-
lation.
Most existing general health measures are
focused on health-related quantity and qual-
ity of life changes. This makes sense because
maximising health gain is a very important
objective. PSU, however, affects a number
of other dimensions of life quality of both
users and their families. Some PSU-related
outcome measures have attempted to include
some of these dimensions. There is a need
to evaluate whether such “non-health” ben-
efits to PS users can be measured and val-
ued perhaps through “willingness to pay” or
preference-based measures on total health
and non-health-related quality of life. At the
current time, there are no such ready-to-use
economic measures.
The current body of cost-offset and cost
outcome studies suggest that one of the con-
sequences of individuals receiving treatment
is the reduction in demand for other health
services. These potential gains could be size-
able. The ease by which health use can be
measured varies with health care systems.
Where there is some charging mechanism,
even if individuals do not pay directly be-
cause of social insurance, there may be
records of all health care use, including the
resource cost of the different treatment epi-
sodes. However, in many countries it may
be necessary to ask individuals about their
use of health care over a period before, dur-
ing and after treatment and then use average
values of the costs of such use. Cost-offset
studies using insurance record data can track
individuals within the plan over considerable
periods. This would be more difficult to
achieve with self-report data. It is not clear
how accurate recall would be over long pe-
riods especially of frequently used health ser-
vices. This is one of the important challenges
to researchers.
As well as the benefits to the health care sys-
tem, PSU treatments also are likely to re-
duce the use of other social care and welfare
agencies. It should be noted again that these
resources relate to services received rather
than changes to welfare benefits, which are
transfer payments not resource costs. The
difficulty for evaluators is tracing such changes
in use and finding some means of valuing the
diverse range of effects that may arise. It
would of course be far too costly and time
consuming to individually trace all potential
effects. Some may be excluded from the
analysis but the effects of such exclusions has
to be considered carefully. It is clear, for ex-
ample, that there is a large impact on the costs
to the criminal justice system from treating
some dependent drug users. It would be im-
portant to consider whether the alternative
treatments being evaluated had differential
effects on crime before it was decided to
exclude them, even if the main focus of the
study was the impact on health care services.
Some important benefits from successful
treatments may be more and difficult to mea-
sure. For example, an adequate system of
services for PS users may well have a
favourable impact on a community and the
environment over and above some of the
reductions in direct problems. For example,
reductions in crime rates may also produce
reductions in the fear of crime among com-
munity members. Not all consequences of
treatments may be beneficial. It is important
to consider possible negative consequences
of the alternative interventions being evalu-
ated.
Finally, there are the benefits that result from
gains in productivity. As with productivity
costs, there is some debate about the inclu-
sion of such effects and if included how they
should be measured. Treatment is likely to
improve employment prospects and increase
the productivity of those in work. However,
the actual changes will depend on the state
of the local labour market.
PSU...
affects a
number of other
dimensions of
life quality of
both users and
their families.
Not all
consequences
of treatments
may be
beneficial.
It is important
to consider
possible
negative
consequences
of the
alternative
interventions
being
evaluated.
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6. Adjusting costs and benefits
for differential timing
For all costs and consequences, there is a
need to consider the time period over which
any effects will be measured and valued. In
research terms, observed follow-ups are
generally limited in time. In some instances,
epidemiological data may be available to
model plausible outcomes over time includ-
ing an allowance for relapse. In other cases,
assumptions may have to be made and a
range of results presented. It is these types
of issues and how they are resolved which
illustrate some of the assumptions and com-
promises that have to be made in practical
economic evaluations.
Many of the effects from treatment may last
more than one year. This is particularly true
if the interventions under study extend the life
of the participants. However, we tend to put
a lower value on events occurring in the fu-
ture than those that occur in the current year.
One step in an economic evaluation is to
convert all costs and benefits to a “present
value” so that they can be compared. This
process is called discounting. While there is
general agreement on the need to discount
most resource consequences, there is less
agreement on whether future health benefits
should be discounted. Is a life year saved in
this year worth twice as much as a life-year
saved ten years from now? Or should all life-
years saved be treated as equal even if the
saving does not occur until 20 years in the
future? In practice, most guidelines suggest
both discounted and undiscounted figures for
health benefits should be made available to
readers of the study. Discount rates are usu-
ally based on current financial interest rates.
Applying discount rates to data is relatively
easy and tables are available for converting
figures across a number of years to present
values. Tables from Drummond et al., 1997,
are contained at the end of this workbook
for reference purposes.
To illustrate, consider potential gains from
eliminating alcohol related road traffic deaths
in one year. In England and Wales, this would
result in a total gain of 148,500 life years in a
30 year period. Discounting the future gains
of life years at 5 per cent per annum, how-
ever, reduces the total to a figure of 85,800
life years. If a higher discount rate of 10 per
cent was used, the calculated health gain re-
duces to 57,000 life years, less than half the
undiscounted figure.
7. Measuring the incremental costs
and benefits
Lists of costs and benefits are created
in terms of totals (or average per indi-
vidual) associated with each of the al-
ternative treatments. For economic
evaluations, it is important to know
whether the costs or benefits vary with
the level of service provided. Measur-
ing the incremental (or extra) costs and
benefits as more treatment is undertaken
is important for this task.
Clearly, not all costs rise at the same rate as
the number of treatment admissions increases.
There are some fixed costs, such as build-
ings and equipment. As numbers rise, these
fixed costs are spread over a larger number
until some capacity limit is reached. At this
critical point, however treating a few extra
people can involve a large amount of extra
resources. One of the largest inputs into treat-
ment is therapists’ time. This can be regarded
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Marginal costs for a year from standard methadone treatments (1992)
as semi-fixed and obviously the extra costs
of treating an extra client fall until the thera-
pist has a full load.
Other costs and benefits also may change
according to the level of activity. It is there-
fore important to undertake additional
measurement and modelling of costs and ben-
efits to fully understand the processes of differ-
ent therapies as they expand or contract.
Illustration of incremental costs was given in
the study by Bradley et al (1994): see the
table below. In this example, an extra client
is assumed only to require more
consumables, such as methadone. However,
an extra 25 clients would require more staff
and other programme costs, although not
extra building space. In this example, Site C
has the lowest marginal costs for 1 and 25
clients.
For some research questions, the whole study
could be framed in an incremental way. Many
policy decisions concern how much each
programme should be funded rather than a
choice of funding only one. The incremental
approach would be an appropriate way of
evaluating some stepped programme of care.
In this case, the additional benefits and costs
of providing extra units of care against the
alternative of no additional care.
8. Putting the costs and benefits of the
alternatives together and analysing
the results
After valuing all the costs and benefits of the
alternatives, discounting the sums to present
values, and completing some incremental
analysis, the results still need to be brought
together. Review Workbook 2 for more
thorough information about analysing
and reporting research results.
In cost-minimisation studies, the analysis
involves straight comparisons of the costs (or
net costs if some resource, rather than indi-
vidual health benefits, have been included).
For cost-effectiveness and cost-utility stud-
ies, there are two ways of presenting results.
Cost-effectiveness ratios are generally calcu-
lated by comparing the net costs divided by the
individual health outcomes of one programme
to the costs divided by the individual health
outcomes of the second programme. For ex-
ample, one intervention could result in £1000
per quality-life-year (QALY) gained and an-
other £1200 per QALY. These ratios are gen-
erally based on average costs and benefits.
Site A Site B Site C
1 Client 25 Clients 1 Client 25 Clients 1 Client 25 Clients
Methadone & other
client related costs 1,019 49,571 776 41,909 164 28,090
Staff – 296 – 1,335 1,785
Other costs – 5,118 – 11,547 15,822
Marginal costs 1,019 54,986 776 54,791 164 45,697
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The alternative is to compare costs and out-
comes directly:
(Costs1 - Costs2 )/ (Outcomes1 - Outcomes2)
to give a net figure for the difference be-
tween programme 1 and 2 (if the design of
the study is comparing two alternatives in
this way). This is usually calculated using
incremental costs and benefits and can
clearly be adapted for some of the more
complex economic evaluation designs (see
Drummond et al., 1997).
With a simple study comparing two alterna-
tive programmes, there are four possible re-
sults:
• Programme 1 has more benefits and lower
costs than programme 2 (at all levels of
implementation). In this case programme
1 clearly dominates programme 2.
• Programme 2 has more benefits and lower
costs than programme 1 and 2 will domi-
nate 1.
• Programme 1 has more benefits but also
more costs than programme 2. In this case
the decision is not so simple and may de-
pend on whether incremental figures show
an advantage of one over another.
• Programme 2 has more benefits and more
costs than programme 1. Again decision
is unclear.
With cost-benefit analysis, the benefits and
costs are measured in the same unit, money
values, and the results may be presented as
the net benefits of the alternatives (benefits -
costs) or in terms of cost-benefit ratios (costs/
benefits). Ratios are not particularly useful
and can be manipulated because some ben-
efits can be redefined as averted costs and
affect the ratio. Ratios do not give any ideas
of the size of the scale of benefits or costs.
This may be important when comparing
programmes.
The results will be more complex if a more
complex design is used. Similarly, there may
be subsidiary analysis to consider if the de-
sign of the study allows. For example, it may
be possible to consider whether costs or
benefits vary with severity or other charac-
teristics. However, unlike in other areas, there
are no standard measures for case-mix for
substance use services.
9. Testing the sensitivity of results
Undertaking a full economic evaluation re-
quires a large number of assumptions to be
made. It is important to have some idea
whether the overall results of the study would
vary if different assumptions had been taken.
Some assumptions can be tested systemati-
cally by using sensitivity analyses. This may
involve, for example, using different levels of
effectiveness varying the main cost variables
or using different discount rates and assess-
ing the impact on the results.
As Drummond et al. (1997) suggest, sen-
sitivity analysis may be needed when esti-
mates are subject to debate. This may oc-
cur if no estimates are available, the esti-
mates are subject to imprecision, or there
is methodological controversy such as
those surrounding discount rates. Upper
and lower bounds on estimates for the sen-
sitivity analysis can be set by using evidence
from other studies, current practice in the
literature or by soliciting judgements from
those who will be making decisions. Cal-
culations can be made using a combina-
tion of best guess, most conservative and
least conservative estimates.
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Put the information from this workbook to
use for your own setting. Complete these
exercises below.
Remember to use the information from
Workbooks 1 and 2 to help you complete a
full evaluation plan. Review that information
now, if you have not already done so.
1 Decide whether a full economic evalua-
tion is needed or warranted, given your
research questions and your research re-
sources. Is a partial economic evaluation
(reviewed in this workbook) or a cost
evaluation (Workbook 5) more appro-
priate?
2 Decide the scope of your study and the
treatment alternatives that you want to
evaluate. Will you conduct an economic
evaluation within an agency, across sev-
eral agencies, or evaluate wider social
costs?
• Within an agency
• Across several agencies
• Wider social costs
Its your turn
3 Using the information contained in this
workbook, choose the study design that
is most appropriate for your research
questions and resources.
• Cost-minimisation
• Cost-effectiveness
• Cost-utility
• Cost-benefit
• Partial economic evaluation
4 List programme cost sources that you
want to evaluate. If evaluating services
across agencies, decide the common
measurement(s) you will use. Meet with
planners from the other agency(ies) to
achieve consensus on the evaluation
methods.
We have started the list as an aide for
you. Cross out the sources that do not
apply to your situation, and add others
that are not already listed.
1) Costs to service providers
• Capital:
- land
-  buildings
- equipment
- vehicles
• Running costs:
- paid staff
- volunteers
- administrative and managerial
costs
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- building related expenditure
(heating, lighting, maintenance,
etc.)
- consumables including drugs
prescribed and their dispensing
costs, toxicology costs etc.
2) Costs to the individuals and their
families in treatment
• Out of pocket expenses:
- travelling and other direct ex-
penses
- contribution to treatment costs
(if not included in A)
• Leisure time and other costs as-
sociated with input to treatment
costs:
- pain, distress etc. associated
with changing habits, or with pro-
cess of treatment
3) Costs to other agencies or individuals
• Referrals to other health or so-
cial agencies linked to the treat-
ment
• Increases in potential problems
associated with treatment
- leakage of prescribed drugs to
illicit markets
4) Loss of patient productivity costs
5 Decide how you will assess the “benefits”
of treatment. This will depend partly on the
evaluation design that you choose (Exer-
cise 3), and may include a combination of
cost, quality of life, and other outcome
data. Determine what information you
have available, and what other informa-
tion you will still need to find out. If you
need to collect additional data, decide
what method you will use to do this. Re-
view Workbook 2 to help you choose an
appropriate data collection measure.
Here’s a list to get you started. Cross out
items that you will not measure, and add
others as needed.
1) Direct health benefits to the individual
• Quality and quantity of health
improvements:
- exact measurement depending
on economic analysis type
- associated with reduction in
drug use
- reduced risk of injection-trans-
mitted disease
- more healthy lifestyle in general
- less any adverse effects of treat-
ment
2) Non-health improvements in quality of
life for the individual and family
• Reduction in PSU - related
violence
• Improvements in social func-
tioning
• Other benefits to the family
3) Reduced use of other health care in-
terventions
4) Benefits to other agencies
• Reduced use of resources from
other social care and welfare
services
• Reduced criminal justice system
costs
• Benefits net of any adverse con-
sequences to “community and
social environment”
5) Productivity benefits
• Benefits in individual productiv-
ity as a result of the treatment
6 Review what you have planned in
these exercises. Will your plans an-
swer your research questions? Are
your plans realistic, given your re-
search resources? If not, make modi-
fications as needed.
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Conclusion
and a practical
recommendation
In this workbook, we have outlined the ba-
sic principles and practices of economic
evaluations within PSU services and sys-
tems. In undertaking economic evaluations,
it is essential that you pay close attention
to the principles and practices of planning
and implementation as outlined in Work-
books 1 and 2. Trade-offs have to be made
as to the rigour with which you collect and
analyse information to answer your evalu-
ation questions, and the resources you
have available. You must strive to achieve
the best possible information with the time
and resources available to you. You must
carefully document the limitations of your
findings and conclusions. With these prin-
ciples in mind, you will be able to under-
take practical and useful cost evaluations
within your treatment service or system.
After completing your evaluation, you want
to ensure that your results are put to prac-
tical use. One way is to report your results
in written form (described in Workbook
2, Step 4). It is equally important, how-
ever, to explore what the results mean for
your programme. Do changes need to hap-
pen? If so, what is the best way to accom-
plish this?
Return to the expected user(s) of the evalu-
ation with specific recommendations based
on your results. List your recommenda-
tions, link them logically to your results, and
suggest a period for implementation of
changes. The example below illustrates this
technique.
Based on the finding that programme A,
compared to programme B, results in 20%
cost savings yet equivalent quality of life
outcomes, we recommend that
programme A is adopted on a larger-scale
basis.
Remember, economic evaluations are a
critical step to better understanding the day
to day functioning of your PSU services.
It is important to use the information that
economic evaluations provide to redirect
treatment services. Through careful exami-
nation of your results, you can develop
helpful recommendations for your
programme. In this way, you can take im-
portant steps to create a “healthy culture
for evaluation” within your organisation.
30 Evaluation of Psychoactive Substance Use Disorder Treatment
WHO/MSD/MSB 00.2i
References
Bradley, C.J., French, M.T. and Rachal,
J.V. Financing and cost of standard and
enhanced methadone treatment. Journal
of Substance Abuse Treatment, 1994,
11: 433-442.
Dolan, P., Gudex, C., Kind, P. and Will-
iams, A. A social tariff for the EuroQol:
results from a UK general population
survey. Centre for Health Economics Dis-
cussion Paper 138, University of
York:York, 1995.
Drummond, M.F., O’Brien, B., Stoddart,
G.L. & Torrance, G.W. Methods for the
Economic Evaluation of Health Care
Programmes. 2nd edition, Oxford Medical
Publication: Oxford, 1997.
French, M.T., Mauskopf, J.A., Teague, J.L..
& Roland, E.J. Estimating the dollar value
health outcomes from drug-abuse interven-
tions. Medical Care, 1996, 34(9): 890-910.
Gerstein, D.R., Johnson, R.A., Harwood,
H.J., Fountain, D., Suter, N. and Malloy, K.
Evaluation recovery services: the Califor-
nia drug and alcohol treatment assessment
(CALDATA). California Department of Al-
cohol and Drug Programs: Sacramento,
1994.
Glazer, W.M. and Ereshefsky, L. A
pharmaeconomic model of outpatient antip-
sychotic therapy in “revolving door” schizo-
phrenic patients. Journal of Clinical Psy-
chiatry, 1996, 57(8): 337-345.
Johannesson, M., Jönsson, B., & Karlsson,
G. Outcome measurement in economic
evaluation. Health Economics, 1996, 5(4):
279-296.
Zarkin, G.A., French, M.T., Anderson, D.W.
& Bradley, C.J. A conceptual framework
for the economic evaluation of substance
abuse interventions. Evaluation and Pro-
gram Planning, 1994,17(4): 409-414.
31Workbook 8  •  Economic Evaluations
WHO/MSD/MSB 00.2i
The following case example presents a modi-
fied cost-effectiveness economic evaluation.
The evaluation compared a case management
approach to a “usual care” approach for
people with severe mental illness and PSU
dependence. In this evaluation, case man-
agement included intense individualised as-
sistance and monitoring by a team of profes-
sionals. Usual care was defined as
participation in a community-based PSU sup-
port group (Alcoholics/Narcotics Anony-
mous). Costs of providing each programme
were calculated on a per client basis, and
compared against changes in societal costs
that were incurred by participants. Societal
costs included psychiatric, medical, legal, and
family resources. Results indicated that both
treatments resulted in cost savings. However,
the case management approach also resulted
in significantly improved psychiatric symp-
toms and role functioning relative to usual
care. Evaluators did not provide a cost-ef-
fectiveness ratio, thus departing from stan-
dard cost-effectiveness evaluation techniques
as described in this workbook. As a result,
their conclusions had to be based on a gen-
eral overview of cost and outcome data rather
than a single measure of effectiveness.
Comments about
case example
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Who was asking the
question(s) and why
did they want the
information?
Towards the late 1980’s, a California county
mental health administrator was very much
concerned about the rising costs of mental
health care and the prevalence of substance
misuse. The administrator was searching for
a services program which might be able to
contain the rising costs of care, and, perhaps
at the same time, improve the mental health
status and functioning of clients. In response,
the county allocated funds for carrying out
alternative models for treatment. At the same
time, evaluation funding from the federal gov-
ernment was received to evaluate the costs
and outcomes of this experiment.
This case study focuses on the treatment of
people with severe mental illness and alco-
hol and drug abuse in a California county
(Jerrell & Hu, 1996; Jerrell, Hu, & Ridgeley,
1994; Jerrell & Ridgeley, 1995). A case
management program was developed for this
client population since they are very high us-
ers of public health and other services. The
case management program involved inten-
sive individualised assistance and monitoring
by a team of clinicians and paraprofession-
als. The clients involved in the case manage-
ment program were compared to those in-
volved with Alcoholics Anonymous or
Narcotics Anonymous (AA/NA), a form of
supportive counselling to help people work
through the 12-step recovery process. Staff
met with clients both individually and in groups
and provided an additional three to four hours
per week of services in addition to their men-
tal health services. Staff actively engaged in
teaching patients the 12-step recovery ap-
proach, and linked them to existing AA/NA
meetings in the community. Thus, the 12-step
AA/NA approach served as the control
group or as a “usual care” group.
Qualified patients were randomly assigned
into the two intervention programs. In the fi-
nal analysis, 39 patients were in the AA/NA
program and 45 patients were in the case
management program. It was anticipated that
the individualised assistance and monitoring
within the case management program would
produce superior outcomes for this client
population and be more cost-effective.
The author alone is
responsible for the
views expressed in
this case example.
Case example of a
economic evaluation
Cost-effectiveness evaluation of
substance misuse interventions
By
Teh-wei Hu, Ph.D.
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What resources
were needed to
collect and interpret
the information?
To carry out this evaluation, the director of
the evaluation department in the county re-
cruited a health economist and a clinical psy-
chologist to design the study. Two graduate
students and two staff were hired to collect
and process the data. Outcome data were
collected from personal interviews, and cost
data were mainly collected from county ser-
vices claim records and personal interviews
with clients and their families.
How were the
data collected?
Outcomes - This study examines the out-
comes of treatment of dual diagnosis clients.
It placed much emphasis on psychiatric and
substance disorder symptoms, social func-
tioning, and life satisfaction. Outcome infor-
mation was collected from several survey
instruments: the Social Adjustment Scale
(SAS), (Schooler et al., 1979), the Role
Functioning Scale (RFS), (Green et al.,
1987), and the Satisfaction with Life Scale
(SLS), (Stein and Test, 1980), augmented
information on client use of drugs and alco-
hol, and their mental health and medical con-
ditions.
Costs - Resources utilised by clients with
severe mental and substance disorders in
each of these intervention programs involve
the public and private mental health sector,
general medical sector, judicial system, so-
cial service agencies, and families. Data were
collected on all these sources of support.
Intensive mental health services that were
provided to each client in the study (i.e., in-
patient days, skilled nursing days, residential
treatment days, and emergency visits), were
separated from the mental health supportive
intervention services (i.e., case management
hours, outpatient visits, medication visits, sup-
portive housing days, and day service days).
This was done to compare the cost differ-
ences in providing supportive services through
each intervention. The cost impact of these
programs on the use of other mental health
services, such as acute and subacute, inten-
sive services and non-mental-health services
was then compared.
Data on general medical services were also
collected, because many of these clients
also have co-occurring chronic medical
problems, or have a propensity to seek
treatment in medical emergency or outpa-
tient health services. Medical treatment in-
cluded inpatient, outpatient, and emer-
gency visits, as well as nursing home care.
All these clients were eligible for Medic-
aid, so the costs of these services were
obtained from the billing system in the lo-
cal public hospital or clinics, and from
Medicaid claims data for clients served in
the private sector.
Criminal justice and social services were
provided to some clients in the study as
well. Criminal justice services included
police contacts, arrests, court appear-
ances, attorney services, jail, probation,
and conservator services. The major chal-
lenge in estimating criminal justice costs
was the complexity of the process of re-
trieval and placing a cost value to each unit
of those contacts. Criminal justice system
utilisation data were obtained through the
criminal justice data system. The unit costs
were obtained from the county executive’s
office, which had previously undertaken a
special cost accounting study to determine
what the public’s direct costs were by type
of charge (misdemeanor or felony, drug
related and non-drug related) at each stage
of the criminal justice contact. Data on use
of other social services, including mental
health conservatorship or guardianship,
were collected from client interviews and
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clinical public guardian records. Informa-
tion regarding average cost per unit of
these services were obtained from the rel-
evant departments.
Costs incurred by the family in providing
care to these clients were included in the
cost estimation procedures. This included,
for example, the actual family expenditures
for treatment, transportation, legal services,
as well as the time family members spent
with the client in treatment and transpor-
tation. These data were obtained from fam-
ily/ care giver interviews. Market value of
the transportation costs and wage rate of
services were then used to estimate the
costs to the family. The issue of whether
maintenance costs, such as food, lodging,
and clothing should be included in this type
of analysis is debatable. One approach is
to treat all maintenance costs as treatment
costs (Rice, Kelman, & Miller 1992). An-
other approach is to treat only a portion
of the total as treatment costs (McGuire et
al., 1987). Maintenance costs incurred
while living with family members or alone
in a house are not usually considered treat-
ment costs because these maintenance ex-
penditures are part of daily living expenses,
even of persons who are ill. On the other
hand, in the context of this study, the costs
of employing a paid caretaker to assist a
client with basic daily living activities should
be considered as treatment costs. The lat-
ter reasoning was adopted in these analy-
ses. In this study, we performed a sepa-
rate accounting of all these maintenance
costs to reflect the magnitude of those costs
of daily living. These data were collected
in client and family/ care giver interviews.
Finally, to understand the relevant financial
burdens among various sectors of society,
transfer payments were also recorded in our
data set. Transfer payments are from one
party to another (i.e., parents to children,
government welfare payments, etc.) that are
not accompanied by an exchange of services
or goods of comparable value. These pay-
ments are not treatment costs because they
reflect only a shifting of existing resources.
However, they are an important indicator
reflecting the government/ taxpayer share
of the cost of illness. The amount of trans-
fer payments also serves as a useful out-
come indicator demonstrating treatment
providers’ success in connecting clients to
entitlement programs that are likely to en-
hance overall income level and, therefore,
quality of life. These data are collected
from client interviews as well as from pub-
lic or private guardian records.
After all the public and private service el-
ements related to the evaluation were iden-
tified, we determined a standard unit of
measurement for each type of services and
obtained the unit cost of each service. This
unit cost was then multiplied by the num-
ber of units of services and summed to
obtain various types of subtotal and total
costs.
How were the
data analysed?
Cost and outcome data were compiled for
the 6 months prior to each client’s entry
into the study, and then for each 6-month
period that they remained in the study. Cost
and outcome variable were found using
statistical computing software. Each cost
and outcome variable was summarised
using the mean, variance (standard devia-
tion), minimum, and maximum value, the
use of which provides a basic understand-
ing of these variables and also helps to
check for any possible outliers or unrea-
sonable values. A number of cross-tabu-
lations were constructed with socio-demo-
graphic variables (age, gender, ethnicity,
etc.) to provide a description of the study
populations between study groups. To
evaluate the possible differences be-
tween programs, multiple regression
analysis was used for cost and outcome
data analysis.
35Workbook 8  •  Economic Evaluations
WHO/MSD/MSB 00.2i
What did they find out?
Psychiatric symptoms include depression,
manic episodes, and schizophrenia while
using drugs and alcohol. Compared to the
AA/NA program, patients under case man-
agement had an overall lower mean value
of schizophrenia symptoms and depres-
sion. There was no difference in drug and
alcohol use. These results were obtained
after controlling for sociodemographic dif-
ferences and baseline illness condition us-
ing multiple regression analysis. Overall life
satisfaction measures showed that case
management program patients improved in
terms of their living situation, global satis-
faction with life situation, and mental health
condition, as compared to AA/NA pro-
gram patients. The overall role functioning
measures show that case management pro-
gram patients improved in independent liv-
ing, but were rated lower in extended so-
cial involvement in the community, as
compared to AA/ NA program patients.
Again, all these findings are based on mul-
tiple regression models, controlling for
other sociodemographic factors.
Changes of psychosocial outcome mea-
sures scores were measured and com-
pared between the baseline and 12-month
period through regression analysis. It was
found that adjustment of family interaction
(SAS) was improved by 0.75 for case
management clients, as compared to AA/
NA clients. Similarly, the score of Global
Satisfaction of Life (SLS) for higher for
case management clients by 1.74. Further-
more, mental health symptoms (Schizo-
phrenia, -1.88; Depression, -2.19; Mania,
-0.96) were all reduced among case man-
agement clients as compared to AA/NA
clients.
The findings from these effectiveness mea-
surements indicate that the case manage-
ment program provides some improvement
in psychiatric symptoms, life satisfaction
measures, and independent living, but no
significant improvement in drug or alcohol
symptoms.
Tables 1 and 2 provide a summary of men-
tal health costs and average societal costs
for the two interventions. The detailed cat-
egories of these costs changes over a 12-
month period are illustrated. It can be seen
that both programs significantly reduced
mental health costs from the baseline pe-
riod: AA/NA program reduced costs by
50%, while the case management program
reduced costs by 41.2%. Similarly, total
average societal costs were reduced
46.8% for the AA/NA program, the case
management program reduced costs by
39.7%.
When comparing effectiveness measure-
ments, it seems that case management is
more cost effective than the AA/NA pro-
gram. The AA/NA reduced costs by 10%,
but had less improvement in patient out-
comes. On the other hand, the case man-
agement program achieved both cost re-
duction (4%), and improved some of the
psychosocial conditions of participating
patients.
Given the nature of multiple outcome mea-
sures in numerous scales, it is very difficult
to provide a meaningful cost-effectiveness
ratio. However, it is clear from this analy-
sis that the case management program has
not only reduced (or saved) the costs of
treatment, but also improved the outcomes
of participating clients. In other words, it
achieved both cost savings and improved
effectiveness.
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Table 1: Changes in average mental health service costs per client for two dual
diagnosis treatment programs
AA/NA Case management
Service (n=39) (n=45)
Baseline 12 months % Change Baseline 12 months % Change
Intensive mental health services
Inpatient 7,660 2,196 -71% 2,860 1,563 -45%
Skilled nursing 1,158 159 -86% 1,606 707 -55%
Residential 568 384 -32% 701 201 -71%
Emergency 405 184 -55% 426 157 -63%
Subtotal 9,791 2,923 -70% 5,593 2,628 -53%
Supportive mental health services
Medication 724 604 -17% 794 565 -29%
Outpatient 1,852 1,870 +1% 1,611 1,251 -22%
Case management 466 602 +24% 506 539 -7%
Housing 349 485 +39% 460 378 -18%
Day services 196 189 -4% 237 100 -58%
Partial hospitalization 0 0 0 94 0 -100%
Subtotal 3,587 3,750 +5% 3,702 ,833 23%
Total Costs $13,378 $6,673 -50% $9,295 $5,461 -41%
How were the
results used?
These two programs have achieved cost
savings primarily because of the major re-
duction in the use of intensive mental health
services. Therefore, the dual diagnosis
treatment programs studied succeeded in
their goal to reduce cost.
The findings of this evaluation were re-
ported by the county director of evalu-
ation to the Director of the Bureau of
Mental Health Services, the County
Medical Director, and the County Su-
pervisor. As a result, the County de-
cided that case management programs
should be continued and clients should
be encouraged to utilise case manage-
ment services so that total care costs are
reduced and treatment outcomes are
improved. In fact, the County has also
expanded case management services to
mental health and juvenile delinquent
services program.
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Table 2: Comparison of average societal cost per client for 12-month time periods for
two dual diagnosis treatments
AA/12-step Program Case management
(n=39) (n=45)
Baseline 12 months % Change Baseline 12 months % Change
Psychiatric
Psychiatric Intensive 9,791 2,923 -70% 5,593 2,628 -53%
Psychiatric Supportive 3,587 3,750 +5% 3,702 2,833 -23%
Subtotal 13,378 6,673 -50% 9,295 5,461 -41%
Medical
Medical Inpatient 134 371 +176% 193 341 +77%
Medical Emergency 377 117 -69% 235 121 -49%
Medical Outpatient 104 27 -74% 6 77 +1183%
Subtotal 615 515 -16% 434 539 +24%
Legal
Court, jail, etc. 1,151 995 -14% 1,657 977 -41%
Conservatorship 23 54 +134% 34 11 -68%
Subtotal 1,174 1,049 -11% 1,691 988 -42%
Family
Support 687 176 -74% 363 139 -62%
Travel 57 55 -4% 41 9 -78%
Subtotal 739 231 -69% 404 148 -63%
Grand total $15,906 $8,468 -47% $11,824 $7,136 -40%
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